Trials / Completed
CompletedNCT01179620
Certoparin in Renal Patients Undergoing Hemodialysis
A Multi-center, Prospective, Open-label, 8-weeks Study to Investigate the Efficacy, Safety and Pharmacokinetics of Certoparin (3000 IU Anti-Xa Bolus, With the Option to Titrate Dose)in the Prophylaxis of Clotting in the Extracorporeal Circuit in Patients Undergoing Chronic Hemodialysis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 109 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess the efficacy, safety and pharmacokinetics of certoparin when used to prevent clotting during hemodialysis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Certoparin | Certoparin |
Timeline
- Start date
- 2010-11-01
- Primary completion
- 2011-03-01
- Completion
- 2011-03-01
- First posted
- 2010-08-11
- Last updated
- 2012-07-10
Locations
9 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT01179620. Inclusion in this directory is not an endorsement.